Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 8/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276255 | 0.90 | MGLL (0.68) | CCR8ALDH1A1MGLLKDM4ELMNA | |
| SCHEMBL2074176 | 0.89 | CCR8 (0.69) | CCR8KCNH2ALDH1A1CYP2D6CYP3A4 | |
| SCHEMBL12526355 | 0.88 | CYP2D6 (0.69) | ALDH1A1CYP2D6CYP3A4USP2MAPK1 | |
| SCHEMBL896968 | 0.86 | FAAH (0.63) | CCR8KCNH2MGLLFAAH | |
| SCHEMBL5197063 | 0.86 | CCR8 (0.74) | CCR8KCNH2ALDH1A1CYP2D6CYP3A4 | |
| SCHEMBL30758661 | 0.85 | FAAH (0.61) | CCR8KCNH2MGLLFAAH | |
| SCHEMBL20490879 | 0.85 | FAAH (0.61) | CCR8KCNH2MGLLFAAH | |
| SCHEMBL27161642 | 0.84 | CYP2D6 (0.52) | CCR8KCNH2ALDH1A1CYP2D6CYP3A4 | |
| SCHEMBL14026999 | 0.84 | CYP2D6 (0.63) | ALDH1A1CYP2D6CYP3A4USP2MAPK1 | |
| SCHEMBL2451021 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MGLLKDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1869046-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1869044-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107253-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107252-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | CCR8, CCR1, CCR10 | CCR8 1/4885KCNH2 3170/4885ALDH1A1 697/4885 |
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | CCR8, CCR1, CCRL2 | CCR8 1/4885KCNH2 3095/4885ALDH1A1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.